FPT Achieves Select Tier Partnership with Databricks, Strengthening Its Regional and Global Data & AI Capabilities
The Select Tier is the second-highest level in the Databricks partner ecosystem. It recognizes partners who demonstrate a strong track record of expertise, delivery capability and alignment with Databricks technologies. FPT achieved this status through significant investment in talent development, with nearly 100 technical certifications and over 40 certifications in pre-sales and leadership roles across its team.
This recognition builds on the companies' recent partnership to drive AI-powered digital transformation in Japan. Across the APJ region, FPT has successfully delivered Databricks solutions for major global enterprises in industries such as insurance, manufacturing and energy. These projects have solved complex data challenges, built modern data platforms and accelerated AI adoption across the business.
As a Select Tier Partner, FPT has access to a range of exclusive benefits from Databricks, including expert training, enhanced technical support and closer sales collaboration. These advantages enable FPT to offer even greater value to enterprise clients, especially in key sectors such as banking, manufacturing, and retail, who are pursuing large-scale data transformation.
"Congratulations to FPT on achieving Databricks Select Tier Partner status. This milestone reflects their growing leadership in delivering enterprise-grade data and AI solutions across the region," said Greg Taylor, Vice President of Partners, APJ, Databricks. "By combining FPT's local expertise with the power of the Databricks Data Intelligence Platform, we're helping more customers across APJ modernise their data foundations, operationalise AI at scale, and turn data into timely, actionable insights that drive meaningful business outcomes."
Commenting on the announcement, Frank Bignone, FPT Software Vice President and Director of Digital Transformation Division, FPT Corporation, added: "We are proud to reach this Select Tier Partnership with Databricks, a global leader in unified data and AI. This milestone reflects our deep commitment to building world-class capabilities in modern data platforms, scalable AI solutions, and enterprise-grade analytics. By combining FPT's global delivery strength and Databricks' cutting-edge technology, we are well-positioned to accelerate data-driven transformation for our clients worldwide."
Looking ahead, FPT continues to deepen its talent capabilities, with a focus on growing the number of professionals certified at the advanced Databricks Data Engineer Professional level. FPT and Databricks are also planning joint events and go-to-market activities in key markets such as the United States and Japan. These initiatives aim to generate new business opportunities and strengthen FPT's position as a trusted data and AI partner on a global scale.
About FPT
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam and operates in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. Committed to elevating Vietnam's position on the global tech map and delivering world-class AI-enabled solutions for global enterprises, the Corporation focuses on three critical transformations: Digital Transformation, Intelligence Transformation, and Green Transformation. In 2024, FPT reported a total revenue of USD 2.47 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT's global IT services, please visit https://fptsoftware.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250709930767/en/
Contacts
Media Contact Mai Duong (Ms.)FPT CorporationFPT Software PR ManagerMCP.PR@fpt.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the 'BioMice' sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice ® platforms—including RenMab™ (fully human antibody), RenLite ® (common light chain), RenNano ® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice ® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice ® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Boston Globe
18 minutes ago
- Boston Globe
AI will bring back old boys' clubs
Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up When the ability to expediently undertake honest evaluation eludes us, we intuitively default to a next-best shortcut: pedigree. Expect a resurgence of reliance on status symbols we may have thought the world was beginning to leave behind — elite diplomas, warm intros, old-fashioned references, a person's ZIP code, race, gender, and maybe even their given and family names. One of the early, wide-scale effects that generative AI will have on labor and capital markets is the return of velvet ropes. Advertisement The logic dates way back. If an artifact's authenticity is in question, validate the artisan by their tribe. We'll see these changes all over. Foundations such as Wellcome Trust are accepting applications for grants from 'established researchers.' It'll go unsaid, but universities will rely more heavily on PhD program rankings when they recruit faculty. Admissions officers who had begun to move away from standardized test scores may now grasp onto any numerical indicators that still seem to justifiably sort applicants, even if only by a hair's breadth. Law firms that started to lean toward 'school-agnostic' hiring policies will reverse course. Advertisement This is cognitive triage rather than malice. AI already is doing many wonderful things for us, but it has massively diluted our ability to assess talent and verify authenticity. So gatekeepers everywhere are going to look for logos. In the near term, that will tilt the playing field further away from anyone who lacks status markers. It'll be no surprise if a first-generation college applicant from Fresno whose personal essay might be AI assisted faces more doubt than a legacy or Andover kid who is presumptively the better writer. Likewise, a midcareer coder in Belgrade whose work shows well on GitHub will meet greater suspicion than an MIT grad with a referral, even if both their code repositories were mostly generated with the help of Copilot. The same technology that promises to democratize education, enlarge the circle of creators and productive workers, and equalize talent in the workplace will, ironically, refeudalize selection and recognition in the near term. Whether we end up in a world of more distributed opportunity or more unexamined pedigree may depend on our appetite for doing the harder work of verification or on our willingness to treat outputs of artificial or of human creators as one and the same. Until we acknowledge the latter or we develop new methods to assess and authenticate human capability in an AI-saturated world, the democratic potential of these technologies will be overshadowed by the hierarchies they otherwise might have helped to dissolve. Advertisement
Entrepreneur
18 minutes ago
- Entrepreneur
Presight and Abu Dhabi Police to Drive AI-Enabled Law Enforcement and Smart City Innovation
The partnership will accelerate the deployment of intelligent systems that enable proactive crime prevention, real-time threat detection, digital forensics, and predictive analytics. You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. Presight, an ADX-listed public company with Abu Dhabi-based G42 as its majority shareholder, has entered a strategic cooperation agreement with Abu Dhabi Police General Headquarters (GHQ) to develop cutting-edge artificial intelligence technologies for law enforcement. The collaboration aims to integrate the capabilities of Presight's AI-Policing Suite – a modular, future-ready solution that leverages Generative AI, AI agents, and advanced data analytics – with Abu Dhabi Police's operational excellence to address modern challenges in policing and smart city development. The partnership will accelerate the deployment of intelligent systems that enable proactive crime prevention, real-time threat detection, digital forensics, and predictive analytics. Attending the ceremony were His Excellency Ahmed Saif bin Zaitoon AlMheiri, Commander-General of Abu Dhabi Police, His Excellency Mansoor Al Mansoori, Member of the Abu Dhabi Executive Council, Chairman of the Department of Health - Abu Dhabi, and Vice Chairman of Presight; Thomas Pramotedham, CEO of Presight; and Dr Adel Al Sharji, COO of Presight, and Mohammed AlMheiri, Chief Business Officer - Public Safety & Security. Major General/Engineer Nasir Sultan Al-Yabhouni, Director of the Leadership Affairs Sector at Abu Dhabi Police, said, "Our partnership with Presight helps us benefit from world-leading artificial intelligence technologies that will enhance our policing capabilities and take them to new heights. This collaboration supports our efforts to maintain public safety through innovation, which means strengthening our officers' ability to respond faster, make smarter decisions, and make Abu Dhabi a safer and more secure place." Mohammed AlMheiri, Chief Business Officer - Public Safety & Security, Presight, said, "This strategic agreement marks a pivotal moment in the evolution of AI-driven public safety. Presight, together with Abu Dhabi Police, are enabling a new era of proactive, data-driven law enforcement, which will drive a shift towards applied intelligence-led policing defined by enhancements in decision-making and operational agility. Our platform's intelligent digital investigator, real-time threat detection, and predictive analytics capabilities empower officers to anticipate and respond to challenges with unprecedented speed and precision. Together, we are shaping a future where cities are not only smarter, but fundamentally safer." This strategic alliance supports the transformation of public safety infrastructure, enabling enhanced decision-making and streamlined emergency response. The joint efforts will also explore innovative models to modernize law enforcement practices, emphasizing ethical AI usage and data-driven policing. The partnership is a significant step forward in realizing Abu Dhabi's vision of a future-ready, AI-enabled smart nation, reinforcing its position as a global leader in technology adoption and urban safety.
